Imatinib-induced apoptosis: a possible link to topoisomerase enzyme inhibition

Creative Commons License

Baran Y., Zencir S., Cakir Z., ÖZTÜRK E., TOPÇU Z.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, cilt.36, sa.6, ss.673-679, 2011 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 36 Sayı: 6
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1111/j.1365-2710.2010.01224.x
  • Dergi Adı: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.673-679
  • Abdullah Gül Üniversitesi Adresli: Hayır

Özet

What is known and Objective: Imatinib is a specific BCR/ABL inhibitor, commonly used for the treatment of chronic myeloid leukaemia (CML), a hematological malignancy resulting from a chromosomal translocation that generates the BCR/ABL fusion protein. Recent studies showed that the imatinib has cytotoxic and apoptotic effects on many BCR/ABL-negative cancers. Numerous compounds with cytotoxic potential exert their functions by interfering with the DNA topoisomerase. In this study, we examined the effects of imatinib on tumour cell-killing in relation to DNA topoisomerase enzyme inhibition.